EVOLVD.
Study name | Cholesterol lowering with EVOLocumab to prevent cardiac allograft vasculopathy in de‐novo heart transplant recipients (EVOLVD) |
Methods | Parallel arm RCT |
Participants | De novo heart transplant recipients |
Interventions | Evolocumab Placebo |
Outcomes | |
Starting date | November 2018 |
Contact information | |
Notes |